Trial Search Results

Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme

This study is designed to evaluate the clinical activity of CDX-110 vaccination when given with standard of care treatment (maintenance temozolomide therapy). Study treatment will be given until disease progression and patients will be followed for long-term survival information. Efficacy will be measured by the progression-free survival status at 5.5 months from the date of first dose.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Celldex Therapeutics

Stanford Investigator(s):


  • Drug: CDX-110 with GM-CSF
  • Drug: Temozolomide


Phase 2


Inclusion Criteria:

   - Newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue.

   - Gross total resection followed by conventional chemoradiation therapy without
   progression of disease.

Exclusion Criteria:

   - Presence of diffuse leptomeningeal disease or gliomatosis cerebri.

   - Systemic corticosteroid therapy > 2 mg of dexamethasone or equivalent (as defined by
   the investigator) per day at study enrollment.

   - Patients who have undergone stereotactic radiosurgery prior to or following surgical
   resection, or the placement of Gliadel® Wafers.

   - Known allergy or hypersensitivity to KLH, GM-CSF or yeast derived products, or a
   history of anaphylactic reactions to shellfish proteins.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting